Nanoscope Therapeutics Revenue and Competitors

Location

#9165

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Nanoscope Therapeutics's estimated annual revenue is currently $2.6M per year.(i)
  • Nanoscope Therapeutics's estimated revenue per employee is $77,500
  • Nanoscope Therapeutics's total funding is $13M.

Employee Data

  • Nanoscope Therapeutics has 34 Employees.(i)
  • Nanoscope Therapeutics grew their employee count by 26% last year.

Nanoscope Therapeutics's People

NameTitleEmail/Phone
1
Co-Founder & PresidentReveal Email/Phone
2
CFOReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
VP QualityReveal Email/Phone
5
VP Regulatory AffairsReveal Email/Phone
6
SVP, Regulatory AffairsReveal Email/Phone
7
VP Global Research & DevelopmentReveal Email/Phone
8
VP Clinical OperationsReveal Email/Phone
9
Director IP & Project ManagementReveal Email/Phone
10
Director Non-clinical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M11-8%N/AN/A
#2
$14.9M96-6%N/AN/A
#3
$15.2M983%$1.8MN/A
#4
$1.6M100%N/AN/A
#5
$3.4M220%N/AN/A
#6
$2.8M1850%N/AN/A
#7
$7.4M48-2%N/AN/A
#8
$0.8M50%N/AN/A
#9
$1.6M100%N/AN/A
#10
$16.3M10562%N/AN/A
Add Company

What Is Nanoscope Therapeutics?

Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa

keywords:N/A

$13M

Total Funding

34

Number of Employees

$2.6M

Revenue (est)

26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Nanoscope Therapeutics News

2022-04-20 - Nanoscope's Vision Restoring Optogenetic Gene Therapy to ...

About Nanoscope Therapeutics Inc. Nanoscope Therapeutics is developing optogenetic therapies to give sight to millions of patients suffering...

2022-04-13 - Nanoscope Therapeutics Appoints CMO, CDO

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal diseases, has appointed Aaron...

2022-03-30 - Nanoscope Therapeutics Announces 3 New Appointments to ...

Nanoscope's Multi-Characteristic Opsin (MCO) gene therapy platform is designed to restore vision in patients blinded by retinal degenerative...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.9M3442%N/A
#2
$7.3M34-15%N/A
#3
$3.9M34N/AN/A
#4
$7.3M370%N/A
#5
$6.2M37-3%N/A